Skip to Content

625 Results Found

  • Review
  • Open Access
48 Citations
10,930 Views
18 Pages

State of Art of Idiosyncratic Drug-Induced Neutropenia or Agranulocytosis, with a Focus on Biotherapies

  • Emmanuel Andrès,
  • Noel Lorenzo Villalba,
  • Abrar-Ahmad Zulfiqar,
  • Khalid Serraj and ,
  • Rachel Mourot-Cottet and
  • Jacques-Eric Gottenberg
  • + 1 author+ 0 author

1 September 2019

Introduction: Idiosyncratic drug-induced neutropenia and agranulocytosis is seldom discussed in the literature, especially for new drugs such as biotherapies outside the context of oncology. In the present paper, we report and discuss the clinical da...

(This article belongs to the Section Pharmacology)
  • Article
  • Open Access
52 Citations
15,302 Views
20 Pages

Incidence of Capillary Leak Syndrome as an Adverse Effect of Drugs in Cancer Patients: A Systematic Review and Meta-Analysis

  • Gwang Hun Jeong,
  • Keum Hwa Lee,
  • I Re Lee,
  • Ji Hyun Oh and ,
  • Dong Wook Kim,
  • Jae Won Shin,
  • Andreas Kronbichler,
  • Michael Eisenhut,
  • Hans J. van der Vliet and
  • Jae Il Shin
  • + 12 authors+ 7 authors

26 January 2019

Capillary leak syndrome (CLS) is a rare disease with profound vascular leakage, which can be associated with a high mortality. There have been several reports on CLS as an adverse effect of anti-cancer agents and therapy, but the incidence of CLS acc...

(This article belongs to the Section Vascular Medicine)
  • Review
  • Open Access
82 Citations
22,574 Views
13 Pages

Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab

  • Despoina Florou,
  • Maria Katsara,
  • Jack Feehan,
  • Efthimios Dardiotis and
  • Vasso Apostolopoulos

20 October 2020

Until recently, in the pathogenesis of Multiple Sclerosis (MS), the contribution of B cells has been largely underestimated, and the disease was considered a T-cell-mediated disorder. However, newer evidence shows that B cells play a crucial role in...

(This article belongs to the Section Molecular and Cellular Neuroscience)
  • Article
  • Open Access
2,530 Views
10 Pages

Design, Synthesis and Biological Evaluation of Novel PEG-Rakicidin B1 Hybrid as Clostridium difficile (CD) Targeted Anti-Bacterial Agent

  • Lijun Xie,
  • Li Chen,
  • Yongbo Wei,
  • Nannan Chen and ,
  • Tong Wu,
  • Jingming Zhou,
  • Hong Jiang and
  • Feng Lin
  • + 3 authors+ 0 author

21 August 2023

Rakicidin B1 was isolated and purified from the culture broth of a marine Streptomyces sp. as a potent anti-cancer agent, and lately the compound and its derivatives have firstly been found to possess anti-Clostridium difficile (CD) activity but with...

(This article belongs to the Special Issue The Design, Synthesis, and Biological Activity of New Drug Candidates)
  • Review
  • Open Access
7 Citations
7,446 Views
20 Pages

25 May 2025

High-risk genetic multiple myeloma (HRMM) remains a major therapeutic challenge, as patients harboring adverse genetic abnormalities, such as del(17p), TP53 mutations, and biallelic del(1p32), continue to experience poor outcomes despite recent thera...

(This article belongs to the Special Issue Novel Insights into Molecular Mechanisms and Therapy of Myeloma)
  • Article
  • Open Access
748 Views
21 Pages

Pneumonitis Associated with Immune Checkpoint Inhibitors and Targeted Anticancer Therapies: A Retrospective Case Series of 12 Patients

  • Claudia Lucia Toma,
  • Ștefania Florina Oprea,
  • Ștefan Dumitrache-Rujinski,
  • Ionela Nicoleta Belaconi and ,
  • Daniela Jipa-Dună,
  • Cristian Cojocaru,
  • Alexandra Maria Cristea,
  • Camelia Cristina Diaconu and
  • Dragos Cosmin Zaharia
  • + 4 authors+ 0 author

27 August 2026

Background: Immunotherapy and targeted therapy have gained ground over conventional chemotherapy in treating various cancers. While pulmonary toxicity associated with these agents is rare, it represents a significant factor in both mortality and morb...

(This article belongs to the Section Respiratory Diseases)
  • Feature Paper
  • Review
  • Open Access
5 Citations
9,889 Views
19 Pages

Targeted Treatment of Follicular Lymphoma

  • Karthik Nath and
  • Maher K. Gandhi

22 February 2021

Follicular lymphoma (FL) is the most common indolent B-cell lymphoma. Advanced stage disease is considered incurable and is characterized by a prolonged relapsing/remitting course. A significant minority have less favorable outcomes, particularly tho...

(This article belongs to the Special Issue Targeted Treatment of Lymphoma, Leukaemia and Myeloma)
  • Article
  • Open Access
9 Citations
3,275 Views
17 Pages

29 December 2021

Scleritis involves inflammation of the sclera, which constitutes 75% of the wall of the eye. This pathology is often seen as an ocular lesion associated with systemic inflammatory diseases. Severe types of scleritis such as posterior scleritis requir...

(This article belongs to the Special Issue Immune Pathogenesis and Regulation of Ocular Inflammation)
  • Review
  • Open Access
145 Citations
16,989 Views
26 Pages

Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab

  • Thomas G. Martin,
  • Kathryn Corzo,
  • Marielle Chiron,
  • Helgi van de Velde and ,
  • Giovanni Abbadessa,
  • Frank Campana,
  • Malini Solanki,
  • Robin Meng,
  • Helen Lee and
  • Kenneth C. Anderson
  • + 8 authors+ 3 authors

26 November 2019

CD38 is a transmembrane glycoprotein with ectoenzymatic activity involved in regulation of migration, signal transduction, and receptor-mediated adhesion. CD38 is highly expressed on various malignant cells, including multiple myeloma (MM), and at re...

(This article belongs to the Special Issue CD38 and Disease: A Bi-Directional Cross-Talk between Pathology and Physiology)
  • Article
  • Open Access
2,299 Views
10 Pages

Efficacy of Anti-CD38 Monoclonal Antibodies for Relapsed or Refractory Multiple Myeloma in Stem Cell Transplant-Ineligible Patients Aged over 65 Years: A Propensity Score-Matched Study

  • Satoshi Yamasaki,
  • Michitoshi Hashiguchi,
  • Nao Yoshida-Sakai,
  • Hiroto Jojima and ,
  • Koichi Osaki,
  • Takashi Okamura and
  • Yutaka Imamura
  • + 2 authors+ 0 author

18 November 2024

Background: The development of newer agents, including anti-CD38 monoclonal antibodies (mAbs), has significantly improved overall survival (OS) in patients with relapsed or refractory multiple myeloma (RRMM). However, the treatment of older patients...

  • Article
  • Open Access
4 Citations
4,297 Views
18 Pages

A Novel In Vitro Model of the Bone Marrow Microenvironment in Acute Myeloid Leukemia Identifies CD44 and Focal Adhesion Kinase as Therapeutic Targets to Reverse Cell Adhesion-Mediated Drug Resistance

  • Eleni E. Ladikou,
  • Kim Sharp,
  • Fabio A. Simoes,
  • John R. Jones and ,
  • Thomas Burley,
  • Lauren Stott,
  • Aimilia Vareli,
  • Emma Kennedy,
  • Sophie Vause and
  • Andrea G. S. Pepper
  • + 13 authors+ 8 authors

3 January 2025

Background/Objectives: Acute myeloid leukemia (AML) is an aggressive neoplasm. Although most patients respond to induction therapy, they commonly relapse due to recurrent disease in the bone marrow microenvironment (BMME). So, the disruption of the B...

(This article belongs to the Special Issue Targeting the Tumor Microenvironment (Volume II))
  • Systematic Review
  • Open Access
3 Citations
5,187 Views
14 Pages

Efficacy and Safety of Anti-CD38 Monoclonal Antibodies in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Randomized Clinical Trials

  • Francisco Cezar Aquino de Moraes,
  • Vitor Kendi Tsuchiya Sano,
  • Artur de Oliveira Macena Lôbo,
  • Francinny Alves Kelly and ,
  • Victória Morbach,
  • Eric Pasqualotto and
  • Rommel Mario Rodríguez Burbano
  • + 2 authors+ 0 author

29 March 2024

The benefit of associating anti-CD38 monoclonal antibodies to proteasome inhibitor (PI)/immunomodulatory agent (IA) and dexamethasone in the treatment of patients with relapsed or refractory multiple myeloma (MM) remains unclear. PubMed, Embase, and...

(This article belongs to the Section Personalized Therapy and Drug Delivery)
  • Article
  • Open Access
110 Citations
9,257 Views
15 Pages

Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer

  • Rüdiger Klapdor,
  • Shuo Wang,
  • Michael Morgan,
  • Thilo Dörk and ,
  • Ulrich Hacker,
  • Peter Hillemanns,
  • Hildegard Büning and
  • Axel Schambach
  • + 3 authors+ 0 author

Novel therapeutic approaches against ovarian cancer (OC) are urgently needed because of its high rate of recurrence even after extensive surgery and multi-agent chemotherapy. We aimed to develop a novel anti-CD24 chimeric antigen receptor (CAR) as an...

(This article belongs to the Special Issue Molecular Mechanisms of Ovarian Cancer Development and Metastasis)
  • Review
  • Open Access
11 Citations
6,852 Views
17 Pages

31 January 2024

One of the most common subgroups of cutaneous T-cell lymphomas is that of primary cutaneous CD30-positive lymphoproliferative disorders. The group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large cell lymphoma (pcALCL), as...

(This article belongs to the Section Hematology)
  • Article
  • Open Access
18 Citations
6,409 Views
19 Pages

Development of a Bispecific Nanobody Targeting CD20 on B-Cell Lymphoma Cells and CD3 on T Cells

  • Yanlong Liu,
  • Kexin Ao,
  • Fuxiang Bao,
  • Yi Cheng and ,
  • Yanxia Hao,
  • Huimin Zhang,
  • Shan Fu,
  • Jiaqi Xu and
  • Qiyao Wu
  • + 4 authors+ 0 author

17 August 2022

B-cell lymphoma is a group of malignant proliferative diseases originating from lymphoid tissue with different clinical manifestations and biological characteristics. It can occur in any part of the body, accounting for more than 80% of all lymphomas...

(This article belongs to the Section Vaccines, Clinical Advancement, and Associated Immunology)
  • Review
  • Open Access
6 Citations
3,305 Views
18 Pages

Pediatric-onset multiple sclerosis (POMS) is a rare yet increasingly recognized demyelinating disease of the central nervous system, characterized by a highly inflammatory disease course and an elevated relapse rate compared to adult-onset MS (AOMS)....

(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
  • Review
  • Open Access
52 Citations
8,355 Views
22 Pages

1 February 2023

In spite of consistent progress at the level of basic research and of clinical treatment, acute myeloid leukemia (AML) still represents an unmet clinical need for adult and pediatric patients. To improve the outcomes of these patients, it is necessar...

(This article belongs to the Special Issue Molecular Mechanisms and Therapies of Myeloid Leukaemia 2.0)
  • Review
  • Open Access
32 Citations
7,571 Views
11 Pages

CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond

  • Dario Roccatello,
  • Roberta Fenoglio,
  • Savino Sciascia,
  • Carla Naretto and ,
  • Daniela Rossi,
  • Michela Ferro,
  • Antonella Barreca,
  • Fabio Malavasi and
  • Simone Baldovino
  • + 4 authors+ 0 author

Immunoglobulin light chain amyloidosis (AL amyloidosis) is a rare systemic disease characterized by monoclonal light chains (LCs) depositing in tissue as insoluble fibrils, causing irreversible tissue damage. The mechanisms involved in aggregation an...

(This article belongs to the Special Issue Monoclonal Antibodies and Their Functional Fragments in Research, Diagnosis and Therapy)
  • Review
  • Open Access
11 Citations
9,283 Views
22 Pages

Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders

  • Jana Mihályová,
  • Katarína Hradská,
  • Tomáš Jelínek,
  • Benjamin Motais and ,
  • Piotr Celichowski and
  • Roman Hájek
  • + 1 author+ 0 author

25 October 2021

Over the last few years, treatment principles have been changed towards more targeted therapy for many B-cell lymphoma subtypes and in chronic lymphocytic leukemia (CLL). Immunotherapeutic modalities, namely monoclonal antibodies (mAbs), bispecific a...

(This article belongs to the Special Issue Novel Approaches to Hematologic Malignancies by Immunotherapy)
  • Article
  • Open Access
1 Citations
3,095 Views
18 Pages

High-Risk Cytogenetic Multiple Myeloma Remains a Therapeutic Challenge: A 15-Year Real-World Analysis

  • Carmel Awadallah,
  • Anas Zayad,
  • Shebli Atrash,
  • Anita Mazloom and ,
  • Omar Alkharabsheh,
  • Prerna Mewawalla,
  • Mansi R. Shah,
  • Forat Lutfi,
  • Zahra Mahmoudjafari and
  • Al-Ola Abdallah
  • + 8 authors+ 3 authors

Background: High-risk cytogenetic multiple myeloma (HRMM) confers inferior outcomes despite significant therapeutic advances. Real-world data characterizing contemporary treatment patterns across lines of therapy in this population are limited. Metho...

(This article belongs to the Special Issue U.S. Myeloma Innovations Research Collaborative (USMIRC) Collection)
  • Feature Paper
  • Article
  • Open Access
7 Citations
6,608 Views
11 Pages

Antibody Therapeutics as Interfering Agents in Flow Cytometry Crossmatch for Organ Transplantation

  • Michael L. Kueht,
  • Laxmi Priya Dongur,
  • Muhammad A. Mujtaba and
  • Matthew F. Cusick

16 June 2023

Donor–recipient matching is a highly individualized and complex component of solid organ transplantation. Flowcytometry crossmatching (FC-XM) is an integral step in the matching process that is used to detect pre-formed deleterious anti-donor i...

(This article belongs to the Section Personalized Therapy in Clinical Medicine)
  • Article
  • Open Access
16 Citations
6,055 Views
11 Pages

Successful Incorporation of Exosome-Capturing Antibody-siRNA Complexes into Multiple Myeloma Cells and Suppression of Targeted mRNA Transcripts

  • Emi Soma,
  • Asako Yamayoshi,
  • Yuki Toda,
  • Yuji Mishima and ,
  • Shigekuni Hosogi and
  • Eishi Ashihara
  • + 1 author+ 0 author

23 January 2022

Nucleic acid medicines have been developed as new therapeutic agents against various diseases; however, targeted delivery of these reagents into cancer cells, particularly hematologic cancer cells, via systemic administration is limited by the lack o...

(This article belongs to the Special Issue Exosome Biology for Nucleic Acid Medicine—From Bench to Bed)
  • Review
  • Open Access
36 Citations
8,575 Views
11 Pages

Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis

  • Giovanni Palladini,
  • Paolo Milani,
  • Fabio Malavasi and
  • Giampaolo Merlini

4 March 2021

Systemic light-chain (AL) amyloidosis is caused by a small B cell, most commonly a plasma cell (PC), clone that produces toxic light chains (LC) that cause organ dysfunction and deposits in tissues. Due to the production of amyloidogenic, misfolded L...

(This article belongs to the Special Issue CD38 and Disease: A Bi-Directional Cross-Talk between Pathology and Physiology II)
  • Review
  • Open Access
3,391 Views
15 Pages

Trifecta of CD-19 Receptor, IgG4 Disease and the Mitigate Trials

  • Rahul Jain,
  • Bipneet Singh,
  • Palak Grover,
  • Jahnavi Ethakota and ,
  • Sakshi Bai,
  • Gurleen Kaur and
  • Merritt Bern
  • + 2 authors+ 0 author

7 September 2025

IgG4-related disease (IgG4-RD) is a subacute, progressive, multisystemic autoinflammatory condition which presents with nonspecific symptoms like weight loss, fatigue and myalgia, and is marked by lymphoplasmacytic infiltrates rich in IgG4-positive p...

  • Article
  • Open Access
14 Citations
7,799 Views
13 Pages

Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model

  • Beatrice Anna Zannetti,
  • Angelo Corso Faini,
  • Evita Massari,
  • Massimo Geuna and ,
  • Enrico Maffini,
  • Giovanni Poletti,
  • Claudio Cerchione,
  • Giovanni Martinelli,
  • Fabio Malavasi and
  • Francesco Lanza
  • + 5 authors+ 0 author

11 December 2020

Multiple myeloma (MM) is a hematological disease characterized by the proliferation and accumulation of malignant plasmacells (PCs) in the bone marrow (BM). Despite widespread use of high-dose chemotherapy in combination with autologous stem cell tra...

(This article belongs to the Special Issue CD38 and Disease: A Bi-Directional Cross-Talk between Pathology and Physiology II)
  • Review
  • Open Access
13 Citations
5,320 Views
9 Pages

Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  • Luis Miguel Juárez-Salcedo,
  • Santosh Nimkar,
  • Ana María Corazón and
  • Samir Dalia

Currently, a significant percentage of patients with DLBCL are refractory or relapse after a first line of immunochemotherapy. Second relapses after autologous stem cell transplantation or chimeric antigen receptor T-cell therapies present few treatm...

(This article belongs to the Special Issue Antibody Therapy for Hematologic Malignancies)
  • Article
  • Open Access
2 Citations
9,485 Views
14 Pages

2-(1H-Benzimidazol-2-yl)-4,5,6,7-tetrahydro-2H-indazol-3-ol, a Benzimidazole Derivative, Inhibits T Cell Proliferation Involving H+/K+-ATPase Inhibition

  • Jin Liu,
  • Ning Huang,
  • Ning Li,
  • Si-Nian Liu and ,
  • Min-Hui Li,
  • Hua Li,
  • Xing-Yan Luo,
  • Yan-Tang Wang,
  • Li-Mei Li and
  • Tai Yang
  • + 7 authors+ 2 authors

24 October 2014

In this study, a benzimidazole derivative named BMT-1 is revealed as a potential immunomodulatory agent. BMT-1 inhibits the activity of H+/K+-ATPases from anti-CD3/CD28 activated T cells. Furthermore, inhibition the H+/K+-ATPases by use of BMT-1 shou...

(This article belongs to the Section Medicinal Chemistry)
  • Review
  • Open Access
15 Citations
9,272 Views
25 Pages

Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development

  • Ahmad Iftikhar,
  • Hamza Hassan,
  • Nimra Iftikhar,
  • Adeela Mushtaq and ,
  • Atif Sohail,
  • Nathaniel Rosko,
  • Rajshekhar Chakraborty,
  • Faryal Razzaq,
  • Sonia Sandeep and
  • Faiz Anwer
  • + 7 authors+ 2 authors

Background: Immunotherapy for multiple myeloma (MM) has been the focus in recent years due to its myeloma-specific immune responses. We reviewed the literature on non-Food and Drug Administration (FDA) approved monoclonal antibodies (mAbs) to highlig...

  • Review
  • Open Access
33 Citations
15,400 Views
21 Pages

Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance

  • Danilo De Novellis,
  • Raffaele Fontana,
  • Valentina Giudice,
  • Bianca Serio and
  • Carmine Selleri

30 December 2022

CD38 and B-cell maturation antigens (BCMAs) are prevalently expressed on neoplastic plasma cells in multiple myeloma (MM), making them ideal therapeutic targets. Anti-CD38 monoclonal antibodies, such as approved daratumumab and isatuximab, are curren...

(This article belongs to the Special Issue Contribution of Cancer-Targeting Drugs toward Faster Clinical Application 2.0)
  • Review
  • Open Access
28 Citations
12,432 Views
32 Pages

Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab

  • Sotirios G. Papageorgiou,
  • Thomas P. Thomopoulos,
  • Athanasios Liaskas and
  • Theodoros P. Vassilakopoulos

10 April 2022

Although rituximab has revolutionized the treatment of diffuse large B-cell lymphoma (DLBCL), a significant proportion of patients experience refractory disease or relapse early after the end of treatment. The lack of effective treatment options in t...

  • Review
  • Open Access
9 Citations
3,685 Views
38 Pages

Novel Therapeutic Approaches in Pediatric Acute Lymphoblastic Leukemia

  • Maria Maddalena Marrapodi,
  • Alessandra Di Paola,
  • Giuseppe Di Feo,
  • Oriana Di Domenico and ,
  • Martina Di Martino,
  • Lucia Argenziano,
  • Marianna Falcone,
  • Daniela Di Pinto,
  • Francesca Rossi and
  • Elvira Pota
  • + 5 authors+ 0 author

24 November 2025

Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy, characterized by the clonal proliferation of immature lymphoid precursors. The distinction between B-cell ALL (B-ALL) and T-cell ALL (T-ALL) is fundamental, as each subtype e...

(This article belongs to the Special Issue Molecular Advances in Pediatric Diseases)
  • Article
  • Open Access
7 Citations
6,187 Views
24 Pages

Synthesis of an Anti-CD7 Recombinant Immunotoxin Based on PE24 in CHO and E. coli Cell-Free Systems

  • Simon K. Krebs,
  • Marlitt Stech,
  • Felix Jorde,
  • Nathanaël Rakotoarinoro and ,
  • Franziska Ramm,
  • Sophie Marinoff,
  • Sven Bahrke,
  • Antje Danielczyk,
  • Doreen A. Wüstenhagen and
  • Stefan Kubick
  • + 5 authors+ 0 author

8 November 2022

Recombinant immunotoxins (RITs) are an effective class of agents for targeted therapy in cancer treatment. In this article, we demonstrate the straight-forward production and testing of an anti-CD7 RIT based on PE24 in a prokaryotic and a eukaryotic...

(This article belongs to the Section Molecular Microbiology)
  • Review
  • Open Access
4 Citations
3,559 Views
16 Pages

13 February 2023

Hypomethylating agents (HMAs) have been used for decades in the treatment of hematologic neoplasms, and now, have gathered attention again in terms of their combination with potent molecular-targeted agents such as a BCL-6 inhibitor venetoclax and an...

(This article belongs to the Section Molecular Immunology)
  • Review
  • Open Access
35 Citations
11,469 Views
28 Pages

Targeting CD38 in Neoplasms and Non-Cancer Diseases

  • Wojciech Szlasa,
  • Jakub Czarny,
  • Natalia Sauer,
  • Katarzyna Rakoczy and ,
  • Natalia Szymańska,
  • Jakub Stecko,
  • Maksymilian Kołodziej,
  • Maciej Kaźmierczak and
  • Ewa Barg
  • + 4 authors+ 0 author

28 August 2022

CD38 is a myeloid antigen present both on the cell membrane and in the intracellular compartment of the cell. Its occurrence is often enhanced in cancer cells, thus making it a potential target in anticancer therapy. Daratumumab and isatuximab alread...

(This article belongs to the Section Cancer Immunology and Immunotherapy)
  • Review
  • Open Access
8 Citations
5,155 Views
39 Pages

Medicinal Chemistry of Anti-HIV-1 Latency Chemotherapeutics: Biotargets, Binding Modes and Structure-Activity Relationship Investigation

  • Yan-Kai Wang,
  • Long Wei,
  • Wei Hu,
  • Pei-Xia Yu and ,
  • Zhong Li,
  • Hai-Peng Yu and
  • Xun Li
  • + 2 authors+ 0 author

20 December 2022

The existence of latent viral reservoirs (LVRs), also called latent cells, has long been an acknowledged stubborn hurdle for effective treatment of HIV-1/AIDS. This stable and heterogeneous reservoir, which mainly exists in resting memory CD4+ T cell...

(This article belongs to the Special Issue Recent Trends on Enzymes Inhibitors and Activators in Drug Research 3.0)
  • Review
  • Open Access
37 Citations
9,717 Views
22 Pages

6 April 2023

Tetraspanin CD81 plays major roles in cell-cell interactions and the regulation of cellular trafficking. This cholesterol-embarking transmembrane protein is a co-receptor for several viruses, including HCV, HIV-1 and Chikungunya virus, which exploits...

(This article belongs to the Section Cancer Drug Development)
  • Article
  • Open Access
17 Citations
6,771 Views
20 Pages

CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents

  • Pamela Becherini,
  • Debora Soncini,
  • Silvia Ravera,
  • Elisa Gelli and ,
  • Claudia Martinuzzi,
  • Giulia Giorgetti,
  • Antonia Cagnetta,
  • Fabio Guolo,
  • Federico Ivaldi and
  • Michele Cea
  • + 18 authors+ 13 authors

15 February 2023

Cancer cells fuel growth and energy demands by increasing their NAD+ biosynthesis dependency, which therefore represents an exploitable vulnerability for anti-cancer strategies. CD38 is a NAD+-degrading enzyme that has become crucial for anti-MM ther...

(This article belongs to the Special Issue Oxidative Stress and NRF2 in Health and Disease)
  • Case Report
  • Open Access
5 Citations
3,714 Views
7 Pages

Successful Switch to Obinutuzumab in a Rituximab-Intolerant Child with Difficult-to-Treat Idiopathic Nephrotic Syndrome

  • Magdalena Drozynska-Duklas,
  • Anna Kranz,
  • Ilona Zagozdzon,
  • Irena Balasz-Chmielewska and ,
  • Ilona Chudzik and
  • Aleksandra Zurowska
  • + 1 author+ 0 author

3 January 2025

Background: Idiopathic nephrotic syndrome (INS) is the most common cause of nephrotic syndrome in children. A hallmark of the disease is the rapid remission of proteinuria following a high dose of steroids. Recurrent disease or steroid dependence are...

(This article belongs to the Section Clinical Pediatrics)
  • Review
  • Open Access
1 Citations
9,962 Views
10 Pages

2 July 2024

Monoclonal antibody (MoAb) therapy has been increasingly used in recent years for hematologic malignancies. The MoAbs anti-CD38 and anti-CD47 are immunoglobulins directed against epitopes that are highly expressed not only on cancer cells, but also o...

  • Article
  • Open Access
428 Views
16 Pages

An Ex Vivo 3D Co-Culture Model of the Bone Marrow Niche Better Predicts Clinically Relevant Epigenetic Target Modulation to Improve Immunotherapy in Multiple Myeloma

  • Christine Greil,
  • Johannes Jung,
  • Julia Felthaus,
  • Dagmar Wider and ,
  • Monika Engelhardt and
  • Ralph Wäsch
  • + 1 author+ 0 author

23 September 2026

Background: In the last decade, treatment options for multiple myeloma have increased remarkably, including antibodies or CAR-T cells targeting myeloma surface markers with unprecedented efficacy. To enhance immunomodulation and clinical efficacy eve...

(This article belongs to the Section Methods and Technologies Development)
  • Review
  • Open Access
34 Citations
10,442 Views
22 Pages

Targeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas

  • Tomas Etrych,
  • Alena Braunova,
  • David Zogala,
  • Lukas Lambert and ,
  • Nicol Renesova and
  • Pavel Klener
  • + 1 author+ 0 author

26 January 2022

Malignant lymphomas represent the most common type of hematologic malignancies. The first clinically approved TDD modalities in lymphoma patients were anti-CD20 radioimmunoconjugates (RIT) 131I-tositumomab and 90Y-ibritumomab-tiuxetan. The later clin...

(This article belongs to the Special Issue Advances in Prognosis and Theranostics of Cancer)
  • Article
  • Open Access
22 Citations
5,624 Views
17 Pages

Thunbergia laurifolia Leaf Extract Increased Levels of Antioxidant Enzymes and Protected Human Cell-Lines In Vitro Against Cadmium

  • Marasri Junsi,
  • Chutha Takahashi Yupanqui,
  • Worapong Usawakesmanee,
  • Alan Slusarenko and
  • Sunisa Siripongvutikorn

Thunbergia laurifolia or Rang Jued has been used as an herbal tea and in folk medicine as a detoxifying agent. Cd contamination is globally widespread and a serious public health problem. The aim of this study was to determine the endogenous antioxid...

  • Article
  • Open Access
2 Citations
2,342 Views
18 Pages

Development of Hydroxamate Derivatives Containing a Pyrazoline Moiety as APN Inhibitors to Overcome Angiogenesis

  • Yangyang Liu,
  • Dongsheng Zhao,
  • Chenghua Zhang,
  • Hui Fang and ,
  • Qingsitong Shen,
  • Zhixian Wang and
  • Jiangying Cao
  • + 2 authors+ 0 author

29 November 2022

Aminopeptidase N (APN) was closely associated with cancer invasion, metastasis, and angiogenesis. Therefore, APN inhibitors have attracted more and more attention of scientists as antitumor agents. In the current study, we designed, synthesized, and...

(This article belongs to the Section Medicinal Chemistry)
  • Review
  • Open Access
15 Citations
9,562 Views
28 Pages

Advances in Hodgkin Lymphoma Treatment: From Molecular Biology to Clinical Practice

  • Corrado Benevolo Savelli,
  • Matteo Bisio,
  • Luca Legato,
  • Filippo Fasano and ,
  • Elisa Santambrogio,
  • Maura Nicolosi,
  • Deborah Morra,
  • Carola Boccomini,
  • Roberto Freilone and
  • Mattia Novo
  • + 6 authors+ 1 author

10 May 2024

Classical Hodgkin Lymphoma (cHL) is a highly curable disease, but around 20% of patients experience progression or relapse after standard frontline chemotherapy regimens. Salvage regimens followed by autologous stem cell transplants represent the his...

(This article belongs to the Section Molecular Cancer Biology)
  • Commentary
  • Open Access
21 Citations
6,106 Views
8 Pages

Multiple sclerosis (MS) has become a common neurological disorder involving populations previously considered to be infrequently affected. Genetic dissemination from high- to low-risk groups is a determining influence interacting with environmental a...

(This article belongs to the Special Issue Multiple Sclerosis: Diagnosis and Treatment)
  • Review
  • Open Access
18 Citations
5,043 Views
12 Pages

23 March 2023

The treatment of multiple myeloma (MM) has greatly evolved these past few years. Recent advances in therapeutics have largely benefited elderly patients now renamed “non-transplant-eligible” (NTE) patients. Since the 1960s, and for severa...

(This article belongs to the Collection Advances in Multiple Myeloma Research and Treatment)
  • Review
  • Open Access
2 Citations
3,448 Views
15 Pages

20 November 2023

This review discusses immunomodulatory drug (IMiDs) sequencing and IMiD-free interval strategies for lenalidomide-refractory myeloma. IMiDs and proteasome inhibitors (PIs) improve clinical outcomes in patients with myeloma; however, refractoriness to...

(This article belongs to the Section Medical Research)
  • Review
  • Open Access
14 Citations
6,860 Views
14 Pages

The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

  • Francesca Bonello,
  • Mariella Grasso,
  • Mattia D’Agostino,
  • Ivana Celeghini and ,
  • Alessia Castellino,
  • Mario Boccadoro and
  • Sara Bringhen
  • + 2 authors+ 0 author

29 December 2020

Elderly transplant-ineligible (NTE) patients represent the majority of patients affected by multiple myeloma (MM). Elderly patients are a highly heterogeneous population, with large variability in health and functional status. Thus, choosing their op...

(This article belongs to the Special Issue Multidrug Therapies Containing Monoclonal Antibodies for Multiple Myeloma)
  • Communication
  • Open Access
6 Citations
2,684 Views
7 Pages

Galectin-1 Induces the Production of Immune-Suppressive Cytokines in Human and Mouse T Cells

  • Kimberly D. Herman,
  • Ian Holyer,
  • Duncan C. Humphries,
  • Anna Adamska and ,
  • James A. Roper,
  • Kristoffer Peterson,
  • Fredrik R. Zetterberg,
  • Anders Pedersen,
  • Alison C. MacKinnon and
  • Robert J. Slack
  • + 5 authors+ 0 author

7 November 2024

Galectin-1 is implicated in several pro-tumourigenic mechanisms and is considered immune-suppressive. The pharmacological inhibition of galectin-1 may be beneficial in cancers in which galectin-1 is overexpressed and driving cancer progression. This...

(This article belongs to the Topic Inflammatory Tumor Immune Microenvironment)
  • Article
  • Open Access
3 Citations
2,647 Views
14 Pages

Disclosing the Novel Protective Mechanisms of Ocrelizumab in Multiple Sclerosis: The Role of PKC Beta and Its Down-Stream Targets

  • Lucrezia Irene Maria Campagnoli,
  • Lara Ahmad,
  • Nicoletta Marchesi,
  • Giacomo Greco and ,
  • Federica Boschi,
  • Francesco Masi,
  • Giulia Mallucci,
  • Roberto Bergamaschi,
  • Elena Colombo and
  • Alessia Pascale
  • + 5 authors+ 0 author

16 August 2024

Ocrelizumab (OCR) is a humanized anti-CD20 monoclonal antibody approved for both Relapsing and Primary Progressive forms of Multiple Sclerosis (MS) treatment. OCR is postulated to act via rapid B cell depletion; however, by analogy with other anti-CD...

(This article belongs to the Section Biochemistry)

of 13